GlassScriptPhysician profile
Carolyn C Borne
NPI 1053694273
$2,502.38
in general payments reported to CMS, 2019-2025
25 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $654 · 2023: $681 · 2024: $506 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.45 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $423.97 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.15 | 2021-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $170.05 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $155.45 | 2022-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $123.27 | 2023 | Vemlidy |
| Regeneron Healthcare Solutions, INC. | $96.16 | 2023 | Dupixent |
| Medtronic, INC. | $60.05 | 2024 | Interstim |
| Pharmacosmos Therapeutics INC. | $59.61 | 2021-2023 | Monoferric |
| Ferring Pharmaceuticals INC. | $54.94 | 2021-2022 | |
| Redhill Biopharma INC. | $54.33 | 2021-2022 | |
| Madrigal Pharmaceuticals | $47.63 | 2024-2025 | Resmetirom, Rezdiffra |
| Celltrion USA INC. | $47.29 | 2024 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $45.33 | 2021-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $38.33 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.96 | 2021-2022 | |
| Amgen INC. | $34.36 | 2022-2023 | Avsola, Amjevita |
| Mallinckrodt Hospital Products INC. | $33.09 | 2022-2023 | Terlivaz |
| Braintree Laboratories, INC. | $30.88 | 2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $30.85 | 2024 | Voquezna |
| Genzyme Corporation | $23.17 | 2025 | |
| Evoke Pharma, INC. | $15.40 | 2022 | |
| Merck Sharp & Dohme LLC | $15.17 | 2023 | Dificid |
| Cumberland Pharmaceuticals, INC. | $13.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Borne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.